Survey of antimicrobial activity of four commonly used third generation cephalosporins tested against recent bacterial isolates from ten American medical centers, and assessment of disk diffusion test performance

Diagnostic Microbiology and Infectious Disease

Volumn 24, Issue 4, 1996, Pages 213-219

  Fuchs, Peter C ^a,e   Barry, Arthur L ^a   Brown, Steven D ^a   Allen, S ^b   Doern, G ^c   Ferraro, M J ^d   Hardy, D ^f   Hindler, J ^g   Jenkens, S ^h   McLaughlin, J ⁱ   Murray, P ^j   Sewell, D ^k  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^f STRONG MEMORIAL HOSPITAL   (United States)

^g UCLA MEDICAL CENTER   (United States)

^h UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

ⁱ UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^j BARNES JEWISH HOSPITAL   (United States)

^k PORTLAND VA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS;

EID: 0030130778     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/0732-8893(96)00028-4     Document Type: Article

References (12)

1. Barry AL, Jones RN (1987) Bacterial antibiotic resistance before and after clinical application in the United States. Bull NY Acad Sci 63:217-230.
2. Barry AL, Jones RN, Thornsberry C, Fuchs PC, Gerlach EH, Sommers HM (1982) Ceftizoxime: Collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, β-lactamase stability, and inhibition. J Antimicrob Chemother 10(supplC):25-44.
3. Emori TG, Gaynes RP (1993) An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microb Rev 6:428-442.
4. Fuchs PC, Barry AL, Thornsberry C, Jones RN, Gavan TL, Gerlach EH, Sommers HM (1980) Cefotaxime: In vitro activity and tentative interpretive standards for disk susceptibility testing. Antimicrob Agents Chemother 18: 88-93.
5. Jacoby GA, Medeiros AA (1991) More extended-spectrum β-lactamases. Antimicrob Agents Chemother 35:1697-1704.
6. Jones RN, Barry AL, Thornsberry C (1983) Ceftriaxone: A summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-μg disks. Diagn Microbiol Infect Dis 1:295-311.
7. Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM (1981) Ceftazidime, a pseudomonas-active cephalosporin: In-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. J Antimicrob Chemother 8(supplB):187-211.
8. Murray P, Jones RN, Allen SD, Erwin ME, Fuchs PC, Gerlach EH (1993) Multilaboratory evaluation of the in vitro activity of 13 β-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagn Microbiol Infect Dis 16:191-203.
9. National Committee for Clinical Laboratory Standards (1993a) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A2. National Committee for Clinical Laboratory Standards, Villanova, PA.
10. National Committee for Clinical Laboratory Standards (1993b) Performance standards for antimicrobial disk susceptibility tests. M2-A5. National Committee for Clinical Laboratory Standards, Villanova, PA.
11. Philippon A, Labia R, Jacoby G (1989) Extended-spectrum β-lactamases. Antimicrob Agents Chemother 33:1131-1136.
12. Thornsberry C, Jones RN, Barry AL, Fuchs PC (1982) Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriological response. Rev Infect Dis 4(suppl):S316-S324.